Silexion Therapeutics reports FY2024 results: net loss $16.5M, cash $1.2M, and progress on SIL204

Silexion Therapeutics Corp

Net loss for 2024 was $16.5 million, compared to $5.1 million in 2023.
Cash and cash equivalents as of December 31, 2024 were $1.2 million, down from $4.6 million.
SIL204 showed significant reduction in primary tumor and metastasis in orthotopic pancreatic cancer models.
Company raised approximately $9.1 million in gross proceeds from financings in early 2025.
LODER Phase 2 trial achieved 56% objective response rate in patients with KRAS G12D/V mutations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.